CAI

EX-99.1

2 cai_ex99-1.htm

EX-99.1

Document

Exhibit 99.1

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests

Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%

IRVING, Texas, August 05, 2026— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

•Reported total revenue of $263.7 million, an increase of 45% over the corresponding prior year period.

•Completed approximately 59,200 clinical cases, an increase of approximately 18% over the corresponding prior year period, including approximately 48,300 MI Profile cases and approximately 10,700 Caris Assure cases.

•Reported gross margin of 68%, an approximate 500 bps improvement over the corresponding prior year period.

•Reported net loss of $0.6 million.

•Reported positive Adjusted EBITDA of $55.7 million.

•Reported positive net cash provided by operating activities of $28.5 million, and positive free cash flow of $6.4 million.

“This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from investments in our commercial engine,” said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. “Our comprehensive approach gives every case real molecular depth, across more than 1.13 million patients with AI trained on it, that depth is what powers Caris Detect. And Detect doesn't stop at finding cancer early, through what we call the Mutational Cleanse, we plan to turn an early signal into personalized immune targets, moving from early detection to early interception. It all comes back to one thing: making precision medicine a reality for every patient.”

Recent Operating Highlights

•Launched Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages.

•Launched and received MolDX approval for Caris ChromoSeq, Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies.

•Launched Caris MI Clarity next-generation prognostic tool that leverages multimodal AI technology and computational pathology to deliver rapid, clinically actionable results for HR+/HER2−, postmenopausal, node-negative early-stage breast cancer patients.

•Announced a share repurchase program of up to $100 million, of which approximately $82.1 million remains available for repurchase under the existing Board authorization.

•Published a study on the Caris Lookback Program demonstrating the ongoing clinical value of comprehensive testing with Caris MI Cancer Seek.

•Published a study showing that whole exome measurement of tumor mutational burden (TMB) results in increased overall survival compared to estimates derived from targeted gene panels.

•Launched the Behind the Diagnosis campaign, spotlighting patient lives transformed by Caris' comprehensive genomic testing.

•Announced a dual listing on NYSE Texas.

•Surpassed 1,130,000 total profiles and 845,000 total matched profiles through June 30, 2026. More than 783,000 whole transcriptome and 733,000 whole exome profiles through June 30, 2026.

Second Quarter 2026 Financial Results

Total revenue was $263.7 million for the three months ended June 30, 2026, compared to $181.4 million for the three months ended June 30, 2025, an increase of $82.3 million, or 45%.

The increase in total revenue was driven primarily by a 55% growth in molecular profiling services revenue, which was $252.3 million for the three months ended June 30, 2026, compared to $162.9 million for the three months ended June 30, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements.

Gross profit, calculated as total revenue less cost of services, for the three months ended June 30, 2026 and 2025, was $179.6 million and $113.7 million, respectively, representing a gross margin of 68% and 63%, respectively.

Operating expenses were $152.7 million for the three months ended June 30, 2026, compared to $131.7 million for the three months ended June 30, 2025, an increase of $21.0 million, or 16%. The increase was primarily driven by headcount-related costs.

Net loss was $0.6 million for the three months ended June 30, 2026, as compared to a net loss of $71.8 million for the three months ended June 30, 2025. Net loss per share attributable to common shareholders, basic and diluted, was $0.00 for the three months ended June 30, 2026, as compared to a net loss per share attrib

EX-99.1

2 cai_ex99-1.htm

EX-99.1

Document

Exhibit 99.1

Caris Life Sciences Reports First Quarter 2026 Financial Results

Revenue growth of 79% driven by strong performance in molecular profiling services

IRVING, Texas, May 07, 2026— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

•Reported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.

•Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corresponding prior year period, consisting of approximately 43,600 MI Profile cases and approximately 9,200 Caris Assure cases.

•Reported gross margin of 65%, an approximate 1,800 bps improvement over the corresponding prior year period.

•Reported net loss of $0.5 million.

•Reported positive Adjusted EBITDA of $26.2 million.

•Reported positive net cash provided by operating activities of $32.9 million, and positive free cash flow of $22.5 million, inclusive of annual bonus payments of $30.5 million.

“We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach,” said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. “We are also encouraged by the Achieve 1 data, including the blinded readout, which demonstrates the superior performance of our whole genome technology over inferior techniques such as methylation. We remain focused on strengthening Caris Detect through the incorporation of additional pillars in advance of our upcoming launch.”

Recent Operating Highlights

•Re-aligned sales force in January 2026, and exited at a quarterly run-rate of approximately 56,000 completed cases for February and March.

•Reported Achieve 1 study results reinforcing the superior sensitivity and specificity of Caris Detect.

•Launched and received MolDX approval for Caris ChromoSeq, Caris’ comprehensive whole genome tumor profiling assay for myeloid malignancies.

•Launched Caris MI Clarity next-generation prognostic tool that leverages multimodal AI technology and computational pathology to deliver rapid, clinically actionable results for HR+/HER2−, postmenopausal, node-negative early-stage breast cancer patients.

•Powered by comprehensive approach of whole exome and whole transcriptome, launched the following new Caris AI Insights:

◦Guiding first-line therapy selection and treatment de-escalation in pancreatic cancer

◦Identifying early platinum resistance in ovarian cancer

◦Identifying the benefit or harm from the addition of chemotherapy for NSCLC patients

•Surpassed 1,070,000 total profiles and 790,000 total matched profiles through March 31, 2026.

◦More than 677,000 whole exome and 728,000 whole transcriptome profiles through March 31, 2026.

•Refinanced $400 million credit facility at a lower borrowing cost and secured access to additional strategic capital from Blue Owl and Blackstone.

First Quarter 2026 Financial Results

Total revenue was $216.2 million for the three months ended March 31, 2026, compared to $120.9 million for the three months ended March 31, 2025, an increase of $95.3 million, or 79%.

The increase in total revenue was driven primarily by an 85% growth in molecular profiling services revenue, which was $210.8 million for the three months ended March 31, 2026, compared to $114.1 million for the three months ended March 31, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions.

Gross profit, calculated as total revenue less cost of services, for the three months ended March 31, 2026 and 2025, was $141.3 million and $57.1 million, respectively, representing a gross margin of 65% and 47%, respectively.

Operating expenses were $136.1 million for the three months ended March 31, 2026, compared to $115.0 million for the three months ended March 31, 2025, an increase of $21.1 million, or 18%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.

Net loss was $0.5 million for the three months ended March 31, 2026, as compared to a net loss of $102.6 million for the three months ended March 31, 2025. Net loss per share attributable to common shareholders, basic and diluted, was $0.00 for the three months ended March 31, 2026, as compared to a net loss per share attributable to common shareholders, basic and diluted, of $3.57 for the three months ended March 31, 2025.

Net cash provided by operating activities was $32.9 million for the three months ended March 31, 2026, as compared to net cash used in operating activit

EX-99.1

2 cai_ex99-1.htm

EX-99.1

Document

Exhibit 99.1

Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Full year revenue growth of 97% driven by strong performance in molecular profiling services

Expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion

IRVING, Texas, February 26, 2026— Caris Life Sciences, Inc. (NASDAQ: CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter and full year ended December 31, 2025.

Fourth Quarter 2025 Financial Highlights

•Reported total revenue of $292.9 million, an increase of 125% over the corresponding prior year period.

•Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% over the corresponding prior year period, and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.

•Reported gross margin of 75%, an approximate 2,000 bps improvement over the corresponding prior year period.

•Reported net income of $82.0 million.

•Reported positive Adjusted EBITDA of $106.1 million.

•Reported positive net cash provided by operating activities of $44.8 million, and positive free cash flow of $39.7 million.

Full Year 2025 Financial Highlights

•Reported total revenue of $812.0 million, an increase of 97% over the corresponding prior year.

•Completed approximately 199,300 clinical therapy selection cases, an increase of approximately 22% over the corresponding prior year, and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.

•Reported gross margin of 66%, an approximate 2,300 bps improvement over the corresponding prior year period.

•Reported net loss of $68.1 million.

•Reported positive Adjusted EBITDA of $137.7 million.

•Reported positive net cash provided by operating activities of $83.2 million, and positive free cash flow of $66.9 million.

“Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris and an important step forward for precision medicine,” said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences.

Recent Operating Highlights

•Surpassed 1,016,000 total profiles and 740,000 total matched profiles through December 31, 2025.

◦More than 627,000 Whole Exome and 678,000 Whole Transcriptome profiles through December 31, 2025.

•Announced partnership with Everlywell to launch Caris’ forthcoming MCED assay, Caris Detect.

•Announced collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need.

Fourth Quarter 2025 Financial Results

Total revenue was $292.9 million for the three months ended December 31, 2025, compared to $129.9 million for the three months ended December 31, 2024, an increase of $163.0 million, or 125%.

The increase in total revenue was driven primarily by a 199% growth in molecular profiling services revenue, which was $282.1 million for the three months ended December 31, 2025, compared to $94.4 million for the three months ended December 31, 2024. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements across therapy selection solutions.

Gross profit, calculated as total revenue less cost of services, for the three months ended December 31, 2025 and 2024, was $220.9 million and $70.7 million, respectively, representing a gross margin of 75% and 54%, respectively.

Operating expenses were $132.5 million for the three months ended December 31, 2025, compared to $107.7 million for the three months ended December 31, 2024, an increase of $24.8 million, or 23%. The increase was primarily driven by increased stock-based compensation expense and headcount-related costs.

Net income was $82.0 million for the three months ended December 31, 2025, as compared to a net loss of $36.9 million for the three months ended December 31, 2024. Net income per share attributable to common shareholders, basic and diluted, was $0.29 and $0.28 per share, respectively, for the three months ended December 31, 2025, as compared to a net loss per share attributable to common shareholders, basic and diluted, of $1.73, for the three months ended December 31, 2024.

Net cash provided by operating activities was $44.8 million for the three months ended December 31, 2025, as compared to net cash used in operating activities of $38.9 million for the three months ended December 31, 2024, a 215% improvement. The improvement was driven by improved reimbursement from molecular profiling se